- Janus Kinase (JAK) Inhibitor
- Preferentially Active Against JAK-1 and JAK-2
Hematologic Adverse Effects
Pulmonary Adverse Effects
Other Adverse Effects
- Ruxolitinib Withdrawal Syndrome
- Epidemiology: occurs from 1 day-3 wks following ruxolitinib withdrawal
- Physiology: due to abrupt rebound in serum concentrations of IL-6, TNFα, and macrophage inflammatory protein 1B
- Tapering Ruloxitinib
- Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011;86:1188–1191.
- JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787–798
- A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799–807
- Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013;98: 1865–1871
- Ruxolitinib withdrawal syndrome leading to tumor lysis. J Clin Oncol 2013;31:e430–e432.
- Recurrent hypoxemic respiratory failure. Beyond the usual suspects. Ann Am Thorac Soc. 2014 Sep;11(7):1145-8. doi: 10.1513/AnnalsATS.201403-127CC [MEDLINE]
- Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation. Int J Hematol. 2014 Nov;100(5):498-501. doi: 10.1007/s12185-014-1628-5. Epub 2014 Jul 18 [MEDLINE]